The BRIDGE project introduces a new approach that combines digital and face-to-face methods to facilitate the participation of more children in clinical trials and improve access to innovative therapies.

It is part of the PROFIT Project (Personalizing the Approach to Frail Oncology Patients through Assessment and Individualized Intervention), an innovative initiative focused on providing comprehensive care for oncology patients experiencing frailty.

Members of the RBDCOV project, which involves VHIR, gathered at the Palau Macaya to review progress and achievements made during the final phase of the project.

Hypertension, a key risk factor for heart disease that contributes significantly to cardiovascular mortality and morbidity and damage to vital organs, was the focus of this multi-centre study.

The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.

During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.

Active participation by patients and families in studies helps identify more effective therapies that improve quality of life and survival.

The Vall d’Hebron Institute of Research’s Paediatric Cancer and Hematological Diseases Research Group Achieves Promising Results for Acute Graft-Versus-Host Disease.

Irritability in ADHD and BDP is an understudied symptom that has a major impact on patients' quality of life and may even increase the risk of suicide.

So far, 240 volunteers have been recruited within all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine in adolescents aged 12 to 17.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The new protocol has the same efficacy as the standard one, but only a quarter of the duration, reducing dropout rates and side effects.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

A clinical trial with the prototype of the device shows that the use of this technology improves patient monitoring by nurses and reduces post-surgical complications.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.

The BEACON clinical trial, in which Vall d'Hebron participates, has observed that adding Bevacizumab to treatment with different chemotherapy drugs reduces tumor size in a greater number of patients.

The study, which is part of the European RECOMB project, is currently recruiting volunteers.

This clinical trial is part of the European project RBDCOV, led by HIPRA in which Vall d'Hebron participates, whose recruitment is still open.

The project aims to test the HIPRA vaccine against COVID-19 in children (including adolescents) and immunocompromised people.

The new drug improves core symptoms of depression in just three days

This new method improves and streamlines drug development processes

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.